If you have been reading about Proline-rich sequence and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
==== Non-soluble or undissolvable MNPs ==== Other than dissolvable MNPs, needles can also be made out of metal or ceramic that will not dissolve in the body environment. These coated drug needles can deliver consistent concentration of drugs without the needles dissolving in the body. This kind of MNPs has better performance, but compared to the soluble MNPs, metal or ceramic MNPs are the older version of MNPs. Even if the patches are small, the metal or ceramic MNPs may cause several waste issues. Recycling the metal and ceramic are very hard, as the quantity is very small to overcome the cost to recycle. That is why researchers try to develop the dissolvable MNPs with similar characteristic and performance of drug delivery in non-soluble MNPs.
High entry barriers because of demanding technology: the construction of a large-scale plant for the production of biopharmaceuticals by cell culture fermentation costs around $500 million and takes four to six years. As the specifications of the plant and process types for biopharmaceuticals differ substantially from traditional chemical synthesis, they cannot be produced in conventional multipurpose fine chemical plants. High financial exposure, due to high capital intensity (as massive investments are needed at a time when chances of success are still very low) and risk of batch failures (contamination). Unlike the biopharmaceutical start-ups, the emerging big biopharmaceutical companies are adopting the same opportunistic outsourcing policy as larger pharmaceutical companies. Thus, Amgen, Biogen Idec, Eli Lilly, Johnson & Johnson (J&J), Medimmune, Novartis, Roche-Genentech and Pfizer are investing heavily in in-house manufacturing capacity. With three plants in the US, two in Japan and one each in Germany and Switzerland, Roche has the largest production capacity. New developments in expression systems for mammalian and plant cell technology could reduce capacity requirements substantially: the titer in large-scale mammalian production, 2–3 grams/liter, is expected to double to 5–7 by 2015 go up to 10 by 2020. Furthermore, the widespread application of "single-use disposable bioprocessing technology" advantageously substitutes for stainless steel production trains, at least for short production campaigns.
== Procedure == The exact methods of this procedure are not standardized and vary considerably, for example the exact number and locations of the injections and the volume of the injected material. Before the operation, antibiotic prophylaxis may be given. The rectum is prepared with a phosphate enema at least 2 hours before the procedure. The procedure can be carried out under local anesthetic on an out patient basis, or with caudal epidural anesthesia, or with intravenous sedation, or under general anesthesia. Ultrasound guidance may be used during the injections, which is sometimes reported as being more effective than the surgeon simply palpating (feeling) and looking where to inject. The site of the bulking material can be inter-sphincteric (in the space between the IAS and the EAS), submucosal injections (under the mucosal layer, usually just above the dentate line), or within the IAS itself. Injection of the material can be by the different routes: transanal route, trans-sphincteric, intersphincteric, perianal route (going through the muscle complex) or transcutaneous route. As such, there are several different variations of injection location and route:
=== Generic names === Nefazodone is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while néfazodone is its DCFTooltip Dénomination Commune Française and nefazodone hydrochloride is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia.
Duterte placed the Philippines' illegal drugs problem at the forefront of his presidential campaign, warning the Philippines was at risk of becoming a narco-state. Upon entering office, Duterte began a nationwide crackdown against illegal drugs. At the forefront of the campaign's operations was Oplan Tokhang, which involved policemen knocking on the doors of suspected drug users and inviting them to surrender. Some described the anti-drug campaign as a form of genocide against drug users, in part due to Duterte's early comparison of himself to Adolf Hitler. Among Duterte's early actions included naming three Chinese nationals as alleged drug lords in the Philippines, calling for assistance from the New Peoples Army to join the crackdown, and publicly naming 150 public officials allegedly involved in the drug trade. Concerns arose worldwide due to the rising death toll during police operations, and drug suspects reportedly fighting back ("nanlaban") was a common alibi of several policemen involved. At the height of the drug crackdown in his early presidency, Duterte urged the policemen to kill drug addicts, promising to pardon them for performing their duties; Duterte's call prompted thousands to surrender, and observers noted this assurance may have emboldened the police to allegedly execute suspects and plant evidence on them. In August 2016, opposition Senator Leila de Lima launched a probe into extrajudicial killings, focusing on cases that took place during Duterte's tenure as mayor of Davao City.
Sources: en.wikipedia.org
=== Child exploitation in Kenya === An investigation in 2025 found that TikTok was profiting from sexual livestreams in Kenya involving minors, with teenagers as young as 15 using the platform to solicit explicit content. Women in Kenya reported earning money through TikTok Lives, where coded sexual slang and emoji gifts facilitated transactions, with explicit content often delivered via other platforms. TikTok takes a 70% cut of these livestream earnings and has been aware of child exploitation since at least 2022. Many moderators say the company's content policies are ineffective, and digital pimps exploit underage users on the large. Kenya lacks adequate moderation, and TikTok denies any sort of wrongdoing. In response to the exposé, Kenya's Communications Authority (CA) launched a formal inquiry, directing TikTok to remove all sexual content involving minors and submit a detailed plan to strengthen its moderation and child protection systems.
A tablet of micronized progesterone which is marketed under the brand name Luteina is indicated for sublingual administration in addition to vaginal administration and is available in Poland and Ukraine. A progesterone suppository which is marketed under the brand name Cyclogest is indicated for rectal administration in addition to vaginal administration and is available in Cyprus, Hong Kong, India, Malaysia, Malta, Oman, Singapore, South Africa, Thailand, Tunisia, Turkey, the United Kingdom, and Vietnam. An aqueous solution of progesterone complexed with β-cyclodextrin for subcutaneous injection is marketed under the brand name Prolutex in the Czech Republic, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and Switzerland. A non-systemic topical gel formulation of progesterone for local application to the breasts to treat breast pain is marketed under the brand name Progestogel and is available in Belgium, Bulgaria, Colombia, Ecuador, France, Georgia, Germany, Hong Kong, Lebanon, Peru, Romania, Russia, Serbia, Switzerland, Tunisia, Venezuela, and Vietnam. It was also formerly available in Italy, Portugal, and Spain, but was discontinued in these countries. A progesterone intrauterine device was previously marketed under the brand name Progestasert and was available in Canada, France, the United States, and possibly other countries, but was discontinued. Progesterone vaginal rings are marketed under the brand names Fertiring and Progering and are available in Chile, Ecuador, and Peru.
=== Influence on other special forces === Following the post-war reconstitution of the Special Air Service, other countries in the Commonwealth recognised their need for similar units. The Canadian Special Air Service Company was formed in 1947, being disbanded in 1949. The New Zealand Special Air Service squadron was formed in June 1955 to serve with the British SAS in Malaya, which became a full regiment in 2011. Australia formed the 1st SAS Company in July 1957, which became a full regiment of the Special Air Service Regiment (SASR) in 1964. On its return from Malaya, the C (Rhodesian) Squadron formed the basis for creation of the Rhodesian Special Air Service in 1961. It retained the name "C Squadron (Rhodesian) Special Air Service" within the Rhodesian Security Forces until 1978, when it became 1 (Rhodesian) Special Air Service Regiment. Non-Commonwealth countries have also formed units based on the SAS. The Belgian Army's Special Forces Group, which wears the same capbadge as the British SAS, traces its ancestry partly from the 5th Special Air Service of the Second World War. The French 1st Marine Infantry Parachute Regiment (1er RPIMa) can trace its origins to the Second World War 3rd and 4th SAS, adopting its "who dares wins" motto. The American unit, 1st Special Forces Operational Detachment-Delta, was formed by Colonel Charles Alvin Beckwith, who served with 22 SAS as an exchange officer, and recognised the need for a similar type of unit in the United States Army.
Grill E, Loffler S, Winnacker E-L, Zenk MH (1989). "Phytochelatins, the heavy-metal-binding peptides of plants, are synthesized from glutathione by a specific gamma-glutamylcysteine dipeptidyl transpeptidase (phytochelatin synthase)". Proc. Natl. Acad. Sci. USA. 86 (18): 6838–6842. Bibcode:1989PNAS...86.6838G. doi:10.1073/pnas.86.18.6838. PMC 297945. PMID 16594069.
Later in January, NPR reported that "drug-seizure data suggest that the attacks are doing little to stop the flow of illegal narcotics into the United States." On March 6, 2026, the operation expanded to Ecuador when U.S. forces bombed Comandos de la Frontera as part of the Ecuadorian conflict (2024–present). The campaign was formally named on 13 November 2025 by Pete Hegseth, US secretary of defense, as an expansion of an operation bearing the same name announced by the United States Navy on 28 January 2025. It uses a hybrid fleet of vessels with robotics and autonomous systems to detect and combat alleged drug trafficking networks in the Western Hemisphere. According to an assessment by the Drug Enforcement Administration (DEA), the military strikes against suspected drug-trafficking vessels did not reduce the volume of cocaine entering the United States. Instead, the operations forced criminal organizations to change their smuggling techniques and at the same time eroded traditional law enforcement investigative techniques.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.